The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized Trial
Abstract
Long-term use of high-dose corticosteroids often results in bone loss, which may lead to osteoporosis-related fractures. This was a multicenter, double-blind study in which 290 ambulatory men and women receiving high-dose oral corticosteroid therapy (prednisone ≥ 7.5 mg/day or equivalent) for 6 or more months were randomized to receive placebo, risedronate 2.5 mg/day, or risedronate 5 mg/day for 12 months. All patients received calcium 1 g and vitamin D 400 IU daily. The primary endpoint was lumbar spine bone mineral density (BMD) at month 12. Additional measurements included BMD at the femoral neck and trochanter and the incidence of vertebral fractures. Overall, there were statistically significant treatment effects on BMD at 12 months at the lumbar spine (p < 0.001), femoral neck (p = 0.004), and trochanter (p = 0.010). Risedronate 5 mg increased BMD at 12 months by a mean (SEM) of 2.9% (0.49%) at the lumbar spine, 1.8% (0.46%) at the femoral neck, and 2.4% (0.54%) at the trochanter, whereas BMD was maintained only in the control group. Although not powered to show fracture efficacy, we observed a reduction in the incidence of vertebral fractures of 70% in the combined risedronate treatment groups, relative to placebo (p = 0.042). Risedronate was well tolerated, had a good safety profile, and was not associated with gastrointestinal adverse events. We conclude that risedronate increases BMD and potentially reduces the incidence of vertebral fractures in patients with corticosteroid-induced osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis
Adachi, J. D., Bensen, W. G., Brown, J., Hanley, D., Hodsman, A., Josse, R., Kendler, D. L., Lentle, B., Olszynski, W., Ste.-Marie, L.-G., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708073370603 · Cited by 685
Genant, H. K., Grampp, S., Glüer, C. C., Faulkner, K. G., Jergas, M., Engelke, K., Hagiwara, S., & van Kuijk, C. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091002 · Cited by 610
Prevention of Corticosteroid Osteoporosis -- A Comparison of Calcium, Calcitriol, and Calcitonin
Sambrook, P., Birmingham, J., Kelly, P., Kempler, S., Nguyen, T., Pocock, N., & Eisman, J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306173282404 · Cited by 520
Prevalence and incidence of vertebral deformities
Melton, L. J., Lane, A. W., Cooper, C., Eastell, R., O'Fallon, W. M., & Riggs, B. L. (1993) · Osteoporosis International · doi:10.1007/bf01623271 · Cited by 517
Laan, R. F. J. M., van Riel, P. L. C. M., van de Putte, L. B. A., van Erning, L. J. T. O., van't Hof, M. A., & Lemmens, J. A. M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-10-199311150-00001 · Cited by 411
Self-citationBone loss in response to long-term glucocorticoid therapy
LoCascio, V., Bonucci, E., Imbimbo, B., Ballanti, P., Adami, S., Milani, S., Tartarotti, D., & DellaRocca, C. (1990) · Bone and Mineral · doi:10.1016/0169-6009(91)90139-q · Cited by 384
Self-citationTestosterone Therapy in Glucocorticoid-Treated Men
Reid, I. R. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440100065008 · Cited by 365
INTERMITTENT ETIDRONATE THERAPY TO PREVENT CORTICOSTEROID- INDUCED OSTEOPOROSIS
Dachi, J. O. D. A., Ensen, W. I. G. B., Acques, J., Rown, B., Anley, D. A. H., Osse, R. O. J., Endler, D. A. L. K., Entle, B. R. L., Lszynski, W. O. O., Ouis, L., et al. (1997) · Cited by 360
A UK Consensus Group on management of glucocorticoid‐induced osteoporosis: an update
Eastell, R., Reid, D. M., Compston, J., Cooper, C., Fogelman, I., Francis, R. M., Hosking, D. J., Purdie, D. W., Ralston, S. H., Reeve, J., et al. (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00408.x · Cited by 315
Self-citationGlucocorticoid osteoporosis--mechanisms and management
Reid, I. (1997) · European Journal of Endocrinology · doi:10.1530/eje.0.1370209 · Cited by 278
Delmas, P. D., Balena, R., Confravreux, E., Hardouin, C., Hardy, P., & Bremond, A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.955 · Cited by 278
Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study.
Luengo, M., Picado, C., Del Rio, L., Guanabens, N., Montserrat, J. M., & Setoain, J. (1991) · Thorax · doi:10.1136/thx.46.11.803 · Cited by 241
Report assessing vertebral fractures
R., S. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100403 · Cited by 240
Hall, G. M., Daniels, M., Doyle, D. V., & Spector, T. D. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371014 · Cited by 229
Mortensen, L., Charles, P., Bekker, P. J., Digennaro, J., & Johnston, C. C. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4586 · Cited by 220
Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup.
Adachi, J. D., Wg, B., Bianchi, F. A., Cividino, A. A., Pillersdorf, S., Sebaldt, R. J., Tugwell, P., Gordon, M., Steele, M., Webber, C., et al. (1996) · PubMed · Cited by 209
Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study
Siris, E. S., Chines, A. A., Altman, R. D., Brown, J. P., Johnston, C. C., Lang, R., McClung, M. R., Mallette, L. E., Miller, P. D., Ryan, W. G., et al. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.6.1032 · Cited by 141
Self-citationStruys, A., Snelder, A. A., & Mulder, H. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80154-5 · Cited by 135
Boutsen, Y., Jamart, J., Esselinckx, W., Stoffel, M., & Devogelaer, J. (1997) · Calcified Tissue International · doi:10.1007/s002239900334 · Cited by 132
Self-citationSalmon calcitonin nasal spray in the prevention of corticosteroid- induced osteoporosis
Adachi, J. D., Bensen, W., Bell, M. J., Bianchi, F. A., Cividino, A. A., Craig, G. L., Sturtridge, W. C., Sebaldt, R. J., Steele, M., Gordon, M. J., et al. (1997) · Lara D. Veeken · doi:10.1093/rheumatology/36.2.255 · Cited by 110
Quality control of DXA instruments in multicenter trials
Faulkner, K. G., & McClung, M. R. (1995) · Osteoporosis International · doi:10.1007/bf01774010 · Cited by 105
Mortensen, L. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.2.396 · Cited by 105
Corticosteroid-Induced Osteoporosis
Adachi, J. D., Bensen, W. G., & Cividino, A. (1997) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40040-0 · Cited by 84
Risedronate, a Highly Effective Oral Agent in the Treatment of Patients with Severe Paget’s Disease1
Singer, F. R., Clemens, T. L., Eusebio, R. A., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4871 · Cited by 66
Self-citationStandardization of Spine BMD Measurements
Steiger, P., Genant, H. K., Grman, M. E., Hangartner, T. N., Hanson, J., Kalender, W. A., Mazess, R. B., Morita, R., Schießl, H., Steiger, P., et al. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101022 · Cited by 43
Risedronate, a Highly Effective Oral Agent in the Treatment of Patients with Severe Paget's Disease
Singer, F. R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.6.1906 · Cited by 32
Corticosteroid-induced osteoporosis
Adachi, J. D. (1996) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.1996.341184 · Cited by 22
Skingle, S. J., Moore, D., & Crisp, A. (1997) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1997.tb11489.x · Cited by 16
Cited by
Compston, J. E., McClung, M. R., & Leslie, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32112-3 · Cited by 2,449
Papaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A., Jamal, S. A., Kaiser, S. M., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,749
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
Canalis, E., Mazziotti, G., Giustina, A., & Bilezikian, J. P. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0394-0 · Cited by 1,114
Alendronate for the Treatment of Osteoporosis in Men
Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., Adami, S., Weber, K., Lorenc, R., Pietschmann, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430902 · Cited by 973
Self-citationKhosla, S., Amin, S., & Orwoll, E. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 930
Metadata
- Authors
- Reid, D. M., Hughes, R. A., Laan, R. F. J. M., Sacco-Gibson, N. A., Wenderoth, D. H., Adami, S., Eusebio, R. A., & Devogelaer, J.-P.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-06-01
- Volume
- 15
- Issue
- 6
- Pages
- 1006-1013
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2134460604
- Cited by
- 592
- References
- 29
- FWCI
- 40.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.